Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
North Dartmouth, MA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Warrensburg, MO
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Warrensburg, MO
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Omaha, NE
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Omaha, NE
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Papillion, NE
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Papillion, NE
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Skillman, NJ
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Skillman, NJ
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigator Site
mi
from
Canton, OH
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigator Site
mi
from
Canton, OH
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Columbus, OH
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Oklahoma City, OK
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigational Site
mi
from
Lake Oswego, OR
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigational Site
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Medford, OR
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Erie, PA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Erie, PA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigator Site
mi
from
Lincoln, RI
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigator Site
mi
from
Lincoln, RI
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigational Site
mi
from
Charleston, SC
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative site
mi
from
Dallas, TX
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Fort Worth, TX
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Waco, TX
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Waco, TX
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
South Burlington, VT
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
South Burlington, VT
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Centennial, CO
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Centennial, CO
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Caba,
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Sulforaphane Supplementation in Atopic Asthmatics
Sulforaphane Supplementation in Atopic Asthmatics
Status: Enrolling
Updated:  3/7/2016
Environmental Protection Agency at the University of North Carolina
mi
from
Chapel Hill, NC
Sulforaphane Supplementation in Atopic Asthmatics
Sulforaphane Supplementation in Atopic Asthmatics
Status: Enrolling
Updated: 3/7/2016
Environmental Protection Agency at the University of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
Status: Enrolling
Updated:  3/9/2016
North Shore-Long Island Jewish Health System, Division of Allergy/Immunology
mi
from
Great Neck, NY
The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
Status: Enrolling
Updated: 3/9/2016
North Shore-Long Island Jewish Health System, Division of Allergy/Immunology
mi
from
Great Neck, NY
Click here to add this to my saved trials
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Status: Enrolling
Updated:  3/9/2016
PROS
mi
from
Elk Grove Village, IL
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Status: Enrolling
Updated: 3/9/2016
PROS
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Status: Enrolling
Updated:  3/9/2016
PeRC
mi
from
Philadelphia, PA
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3
Status: Enrolling
Updated: 3/9/2016
PeRC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Encinitas, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative site
mi
from
Los Angeles, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative site
mi
from
Los Angeles, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Mission Viejo, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigational Site
mi
from
Orange, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Palmdale, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Palmdale, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Riverside, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Riverside, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Rolling Hills Estates, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
San Diego, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
San Jose, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
San Jose, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Stockton, CA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Stockton, CA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Colorado Springs, CO
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis
mi
from
Denver, CO
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis
mi
from
Denver, CO
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Sarasota, FL
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigator Site
mi
from
Owensboro, KY
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigator Site
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
North Dartmouth, MA
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
St. Louis, MO
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
St. Louis, MO
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Papillion, NE
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Papillion, NE
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Skillman, NJ
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Skillman, NJ
Click here to add this to my saved trials
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated:  3/10/2016
Novartis Investigative Site
mi
from
Cincinnati, OH
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Status: Enrolling
Updated: 3/10/2016
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials